Selegiline (Anipryl)

Selegiline, marketed under the veterinary brand name Anipryl, is an FDA-approved medication for dogs that has transformed the management of canine cognitive dysfunction syndrome (CDS), a progressive neurodegenerative condition affecting aging dogs that is often compared to Alzheimer's disease in humans. This medication belongs to the class of monoamine oxidase type B inhibitors (MAO-B inhibitors), which work by preventing the breakdown of certain neurotransmitters in the brain, thereby improving cognitive function and behavioral symptoms in affected dogs. Anipryl represents one of the few FDA-approved treatments specifically developed and indicated for cognitive decline in dogs, giving veterinarians and pet owners a validated tool for addressing this increasingly recognized condition in the aging canine population.

Selegiline exerts its therapeutic effects primarily by irreversibly inhibiting monoamine oxidase type B (MAO-B), an enzyme responsible for breaking down dopamine and phenylethylamine in the brain. By blocking this enzyme, selegiline increases the availability of dopamine, a neurotransmitter that plays crucial roles in cognition, motivation, movement, and mood regulation. In aging dogs with cognitive dysfunction, dopaminergic pathways are often compromised, contributing to the confusion, disorientation, and behavioral changes characteristic of the condition. Additionally, selegiline may provide some neuroprotective effects by reducing the formation of neurotoxic free radicals that are byproducts of dopamine metabolism by MAO-B.

Anipryl is supplied as flavored tablets in multiple strengths designed to accommodate the range of dog sizes, from small companion breeds to large and giant breeds. The medication is administered once daily, typically in the morning, and can be given with or without food. The flavored formulation helps make administration easier for pet owners of senior dogs who may have difficulty taking medications. Therapeutic effects typically develop gradually over the first few weeks of treatment, and pet owners should understand that improvement may be subtle and progressive rather than dramatic and immediate. Many dogs show meaningful improvement within one to two months of starting therapy, though response varies among individuals.

Beyond cognitive dysfunction, selegiline is also FDA-approved for the treatment of uncomplicated pituitary-dependent hyperadrenocorticism (Cushing's disease) in dogs. In this condition, excessive stimulation of the adrenal glands by the pituitary results in overproduction of cortisol, causing a range of clinical signs. Selegiline's mechanism in treating Cushing's disease differs from its cognitive effects and relates to its influence on dopaminergic regulation of pituitary function. While other treatments for Cushing's disease are often preferred due to higher efficacy, selegiline remains an option for certain cases where other treatments are not suitable or as part of a comprehensive management approach.

Canine cognitive dysfunction syndrome (CDS) is the primary indication for selegiline (Anipryl) and represents a significant clinical need in the aging dog population. As dogs live longer due to advances in veterinary medicine and improved care, cognitive decline has become an increasingly recognized problem affecting a substantial proportion of senior dogs. CDS is characterized by progressive deterioration in cognitive abilities, including changes in memory, learning, awareness, and perception. The condition profoundly affects quality of life for both affected dogs and their owners, as beloved pets may seem to lose their personality, recognition of family members, or ability to navigate familiar environments.

The clinical signs of CDS that selegiline is used to address include disorientation and confusion, even in familiar surroundings, where dogs may appear lost in their own home or fail to recognize family members. Changes in sleep-wake cycles are common, with affected dogs often sleeping more during the day and becoming restless or vocal at night, disrupting the household. House-training regression is frequently seen, as dogs with CDS may forget previously well-established house-training habits and begin eliminating indoors. Changes in social interactions, including decreased interest in attention, play, or interaction with family members, often occur. Some dogs develop increased anxiety, fearfulness, or irritability as cognitive function declines.

The acronym DISHAA is commonly used by veterinarians to help recognize and categorize CDS signs: Disorientation, altered Interactions with family, Sleep-wake cycle changes, House soiling, Activity level changes, and Anxiety. Selegiline treatment aims to improve or stabilize signs across these categories by enhancing dopaminergic neurotransmission in the brain. While selegiline cannot reverse underlying brain pathology or cure CDS, it can improve cognitive function and quality of life for many affected dogs, potentially slowing the progression of clinical signs.

Pituitary-dependent hyperadrenocorticism (PDH), also known as Cushing's disease when caused by pituitary dysfunction, is the other FDA-approved indication for selegiline in dogs. This endocrine disorder results from excessive production of adrenocorticotropic hormone (ACTH) by a pituitary tumor or hyperplasia, leading to overproduction of cortisol by the adrenal glands. Clinical signs include increased thirst and urination, increased appetite, pot-bellied appearance, hair loss, thin skin, and increased susceptibility to infections. Selegiline's role in treating PDH relates to dopamine's inhibitory effect on ACTH secretion from the pituitary, though response rates are generally lower than with other Cushing's disease treatments.

Veterinarians may consider selegiline for dogs showing early signs of cognitive decline before a full CDS diagnosis is established, as early intervention may provide better outcomes than waiting until the condition has progressed significantly. The medication's favorable safety profile makes it reasonable to consider in dogs where CDS is suspected but not definitively confirmed, particularly since there is no definitive diagnostic test for CDS during life. The decision to use selegiline is typically based on clinical signs, exclusion of other medical conditions that could cause similar symptoms, and the owner's observations of behavioral changes consistent with cognitive decline.

Selegiline dosing for dogs with cognitive dysfunction syndrome is based on body weight, with the goal of achieving therapeutic brain concentrations while minimizing the risk of adverse effects. The FDA-approved dose for treating CDS is 0.5 to 1 mg per kilogram of body weight, administered once daily in the morning. Starting at the lower end of the dose range is often recommended, with the option to increase the dose if response is inadequate after one to two months of treatment. The veterinarian will determine the appropriate starting dose based on the individual dog's weight, clinical condition, and any concurrent health issues.

Anipryl tablets are available in several strengths (2 mg, 5 mg, 10 mg, 15 mg, and 30 mg) to accommodate the range of dog sizes. The flavored tablets are designed to be palatable to dogs, making once-daily administration more convenient for pet owners. The medication can be given with or without food, though consistency in administration conditions is recommended. Morning dosing is preferred because selegiline's dopamine-enhancing effects can potentially cause restlessness or sleep disturbances if given later in the day, though this effect varies among individual dogs.

Treatment response to selegiline typically develops gradually over the first several weeks of therapy. Pet owners should be advised that improvement may not be immediately apparent and that patience is required during the initial treatment period. Many dogs show noticeable improvement within four to eight weeks of starting therapy, though some may respond sooner and others may take longer. If no improvement is seen after two months at the initial dose, the veterinarian may recommend increasing to the higher end of the dose range before concluding that the dog is a non-responder.

Selegiline is generally considered a long-term maintenance medication for dogs with CDS, as the underlying neurodegenerative process is progressive and ongoing treatment helps maintain cognitive function and quality of life. Discontinuing the medication typically results in gradual return of clinical signs. Pet owners should understand that treatment does not cure CDS but rather manages symptoms and may slow progression. Regular follow-up evaluations are important for monitoring treatment response and adjusting the management plan as needed.

For the treatment of pituitary-dependent hyperadrenocorticism, higher doses of selegiline are typically used, generally 1 to 2 mg per kilogram once daily. Response to selegiline for Cushing's disease is variable, and veterinarians often prefer other treatments with higher efficacy rates. When selegiline is used for this indication, close monitoring of clinical signs and laboratory parameters is essential for assessing treatment response.

If a dose of selegiline is missed, it should be given as soon as remembered unless it is close to evening, in which case the dose may be skipped to avoid potential sleep disturbances. The regular dosing schedule should resume the following morning. Missed doses should not be doubled, as this increases the risk of adverse effects without improving therapeutic outcomes.

Selegiline is generally well-tolerated by most dogs when administered at the recommended doses for cognitive dysfunction syndrome. The overall incidence of adverse effects in clinical trials was relatively low, making selegiline a favorable option for long-term use in senior dogs. However, like all medications, selegiline can cause side effects in some patients, and pet owners should be aware of potential reactions so they can monitor their dog appropriately and report concerns to their veterinarian. Many side effects that occur are mild and may resolve with continued treatment or dose adjustment.

Gastrointestinal effects are among the more commonly reported side effects of selegiline in dogs. These may include decreased appetite, nausea, vomiting, diarrhea, or changes in stool consistency. These effects are typically mild and often diminish as the dog continues on the medication. If gastrointestinal upset persists or is severe, the veterinarian may recommend giving the medication with food or adjusting the dose. Significant or persistent vomiting or diarrhea should be reported to the veterinarian for evaluation.

Behavioral and neurological effects may occur in some dogs on selegiline. Restlessness, increased activity, or agitation have been reported, which may relate to the medication's dopamine-enhancing effects. These effects are sometimes more noticeable in dogs receiving higher doses or sensitive individuals. Giving the medication in the morning rather than later in the day may help minimize any stimulatory effects. Tremors, disorientation, and behavior changes have been occasionally reported. Some dogs may show hearing changes, though this is uncommon.

Salivation and drooling may occur in some dogs after receiving selegiline. This effect is usually transient and resolves on its own. Skin reactions or itching have been rarely reported and may indicate sensitivity to the medication or its inactive ingredients. Any signs of allergic reaction, such as facial swelling, hives, or difficulty breathing, warrant immediate veterinary attention.

Because selegiline is typically used in senior dogs who may have concurrent health conditions, distinguishing medication side effects from symptoms of other diseases can sometimes be challenging. Pet owners should report any new symptoms or changes in their dog's condition to the veterinarian, who can help determine whether these are related to selegiline therapy. Regular follow-up appointments are important for monitoring overall health and treatment response in older dogs receiving long-term selegiline therapy.

Selegiline is contraindicated in dogs with known hypersensitivity or allergic reactions to selegiline or any component of the Anipryl formulation. Dogs that have previously experienced adverse reactions to selegiline should not receive the medication again. Pet owners should inform the veterinarian of any known drug sensitivities or previous adverse reactions before selegiline is prescribed. Signs of allergic reaction, should they occur, may include facial swelling, hives, difficulty breathing, or sudden collapse, and require immediate veterinary attention.

The concurrent use of selegiline with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), other monoamine oxidase inhibitors, or serotonergic medications is contraindicated due to the risk of potentially fatal serotonin syndrome. This is a critically important contraindication that applies to numerous commonly prescribed veterinary medications. Examples of contraindicated medications include fluoxetine (Prozac, Reconcile), sertraline (Zoloft), paroxetine (Paxil), clomipramine (Clomicalm), amitriptyline, tramadol, and buspirone. A washout period of at least two weeks is required when transitioning between selegiline and any of these medications in either direction.

Products containing amitraz, an antiparasitic agent with MAOI activity, should not be used in dogs receiving selegiline. Amitraz is found in some tick collars and topical treatments, and concurrent use with selegiline could result in dangerous interactions. Pet owners must inform the veterinarian about all flea and tick prevention products their dog is using so that amitraz-containing products can be identified and avoided. Alternative parasite prevention options should be selected for dogs on selegiline therapy.

Pregnancy and lactation status should be considered before prescribing selegiline, as the safety of the medication during pregnancy and nursing has not been established in dogs. While CDS and Cushing's disease typically affect older dogs unlikely to be breeding, the veterinarian should confirm that female dogs are not pregnant or nursing before initiating therapy. Breeding dogs should generally not receive selegiline. If selegiline treatment is essential in a dog of breeding age, appropriate contraceptive measures should be in place.

Drug interactions are a major consideration with selegiline therapy, and complete disclosure of all medications, supplements, and preventive products the dog is receiving is absolutely essential before this medication is prescribed. Selegiline is a monoamine oxidase inhibitor, and this class of drugs has significant potential for dangerous interactions with numerous other substances. The veterinarian must have complete information to ensure safe prescribing and to avoid potentially life-threatening drug combinations.

The most critical drug interactions involve serotonergic medications, which when combined with MAO inhibitors like selegiline can cause serotonin syndrome, a potentially fatal condition. Medications that must not be used with selegiline include selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine), tricyclic antidepressants (clomipramine, amitriptyline), buspirone, tramadol, trazodone, meperidine (Demerol), and dextromethorphan (found in some cough suppressants). A minimum washout period of two weeks is required when transitioning between selegiline and any of these medications. Signs of serotonin syndrome include agitation, tremors, elevated body temperature, rapid heart rate, muscle rigidity, and potentially seizures, requiring immediate emergency veterinary care.

Amitraz-containing products, including certain tick collars and topical parasiticides, should not be used in dogs receiving selegiline due to amitraz's MAOI activity. Combining two MAO inhibitors significantly increases the risk of adverse effects. Pet owners must check all flea and tick prevention products for amitraz content and select alternative options during selegiline therapy. The veterinarian can recommend appropriate parasite prevention products that do not contain amitraz.

Epinephrine and medications that release or potentiate catecholamines may have enhanced effects when used with selegiline due to the latter's effects on monoamine metabolism. This is primarily a consideration for veterinary procedures that might involve these agents. Veterinarians performing procedures on dogs receiving selegiline should be aware of this interaction. Tyramine-containing foods, which can cause hypertensive crisis in humans taking MAO inhibitors, are generally less of a concern in dogs due to differences in dietary habits and physiology, but unusual dietary items should still be discussed with the veterinarian.

Before initiating selegiline therapy for suspected cognitive dysfunction syndrome, veterinarians should perform a thorough medical evaluation to rule out other conditions that could cause similar clinical signs. Metabolic disorders, organ dysfunction, pain, sensory deficits such as hearing or vision loss, and other medical problems can mimic signs of CDS. Appropriate diagnostic testing, which may include blood work, urinalysis, and other assessments, helps ensure that underlying medical conditions are identified and addressed rather than masked by behavioral medication. A diagnosis of exclusion is typically used for CDS, as there is no definitive antemortem diagnostic test.

Pet owners should understand the nature of cognitive dysfunction syndrome and have realistic expectations about treatment outcomes with selegiline. While many dogs show improvement in clinical signs, selegiline does not cure the underlying neurodegenerative process, and CDS is generally progressive over time. Treatment aims to improve quality of life and slow symptom progression rather than restore the dog to their previous cognitive state. Some dogs may show significant improvement, while others may show minimal response despite appropriate dosing. Regular follow-up allows assessment of treatment benefit and adjustment of expectations and management plans as needed.

Monitoring during selegiline therapy should include regular veterinary assessments of clinical signs, overall health, and quality of life. Pet owners can help by keeping notes or diaries documenting behavioral observations, sleep patterns, house-training, and other relevant signs to share at veterinary appointments. Because selegiline is typically used in senior dogs who may develop concurrent health conditions, ongoing monitoring allows early detection of new problems that may arise.

The drug interaction profile of selegiline requires ongoing vigilance throughout therapy. Any time a new medication, supplement, or preventive product is considered for a dog on selegiline, the veterinarian must be consulted to check for potential interactions. This includes over-the-counter products, supplements purchased online or at pet stores, and products obtained from other sources. Even herbal and natural products may interact with MAO inhibitors. Pet owners should understand the importance of complete medication disclosure and should contact their veterinarian before giving any new substance to their dog.

Selegiline should be used with caution in dogs with significant liver disease, as the medication undergoes hepatic metabolism. Impaired liver function could affect drug processing and potentially increase the risk of adverse effects. Veterinarians may recommend liver function assessment before starting therapy and may use lower doses in dogs with hepatic compromise. Similarly, while selegiline is not primarily eliminated by the kidneys, dogs with severe renal disease warrant careful evaluation.

Anipryl (selegiline) tablets should be stored at controlled room temperature between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius), protected from moisture and excessive heat. The medication should be kept in its original container with the lid tightly closed to maintain stability and protect from environmental factors that could degrade the tablets. Storage areas should be dry and away from sources of heat such as stoves, heating vents, or sunny windows. A medication cabinet or drawer in a climate-controlled area of the home provides appropriate storage conditions.

As with all medications, selegiline must be stored securely out of reach of children and pets. While the tablets are flavored to appeal to dogs for easier administration, this also means that dogs might seek out and consume the medication if given access. Accidental ingestion of multiple tablets could cause significant adverse effects. The medication should be stored in a location that is completely inaccessible to pets and children, such as a locked cabinet or high shelf. Pet owners should be particularly careful in multi-pet households to ensure that only the intended patient receives the medication.

Expiration dates should be monitored, and expired medication should not be administered. Over time, medications can lose potency or develop degradation products that may reduce effectiveness or cause harm. When refilling prescriptions, older stock should be used before newer supplies to ensure rotation. If tablets appear discolored, crumbled, or otherwise altered from their original appearance, they should not be used, and replacement medication should be obtained from the veterinarian or pharmacy. Unused or expired selegiline should be disposed of properly through veterinary clinic or pharmacy take-back programs, or following established guidelines for safe medication disposal to prevent environmental contamination and accidental exposure by people, pets, or wildlife.

Selegiline (Anipryl) can be used safely in dogs of all breeds for the treatment of cognitive dysfunction syndrome, as there are no established breed-specific genetic factors that significantly affect this medication's safety or efficacy. Unlike some medications that are affected by the MDR1 gene mutation common in herding breeds, selegiline is not known to have significantly altered pharmacokinetics or increased risk in dogs with this genetic variation. Breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related herding breeds can typically receive selegiline without special precautions related to this mutation. However, as with any medication, individual dogs may show variations in response, and veterinary guidance is important for all patients.

Cognitive dysfunction syndrome can affect dogs of any breed, though some studies suggest certain breeds may be at higher or lower risk. Small breed dogs tend to live longer than large and giant breeds, giving them more opportunity to develop age-related cognitive changes. However, large breed dogs are considered seniors at younger ages than small breeds, potentially developing CDS earlier in chronological terms. The decision to use selegiline is based on clinical signs consistent with CDS and exclusion of other conditions, regardless of breed. All breeds benefit from early recognition and treatment of cognitive decline.

Dosing of selegiline is determined by body weight, and the wide size range among dog breeds is accommodated by the multiple tablet strengths available. Very small breeds may require the lowest strength tablets or fractions thereof, while giant breeds may require multiple tablets to achieve the appropriate dose. Accurate weight measurement is essential for appropriate dosing. The veterinarian will calculate the appropriate dose based on the individual dog's current weight and may adjust the dose over time based on response and any weight changes.

Age is the primary factor affecting selegiline use rather than breed, as cognitive dysfunction syndrome is a condition of older dogs. The age at which dogs are considered senior varies by breed size, with small breeds typically not showing signs of aging until 10 to 12 years or older, medium breeds around 8 to 10 years, large breeds around 7 to 8 years, and giant breeds as early as 5 to 6 years. Regardless of breed, dogs showing signs consistent with CDS should be evaluated and considered for treatment. The veterinarian will assess each patient individually, considering their health status, clinical signs, and overall quality of life when making treatment recommendations.

While selegiline (Anipryl) is the only FDA-approved medication specifically indicated for canine cognitive dysfunction syndrome, several other pharmacological and nutraceutical options may be considered as part of a comprehensive management approach for cognitive decline in senior dogs. These alternatives or adjuncts may be appropriate depending on individual patient factors, response to selegiline, concurrent conditions, and owner preferences. A multimodal approach incorporating various interventions often provides the best outcomes for dogs with CDS.

Nutraceuticals and dietary interventions represent an important component of cognitive support for senior dogs. Diets enriched with antioxidants, omega-3 fatty acids, and medium-chain triglycerides (MCTs) have shown promise in supporting brain health and may be used alongside or instead of pharmaceutical treatment. Supplements containing phosphatidylserine, S-adenosylmethionine (SAMe), apoaequorin, and various antioxidant combinations are marketed for cognitive support in dogs and may provide benefit for some patients. These nutraceuticals generally have favorable safety profiles and can often be used in conjunction with selegiline or as alternatives for dogs that cannot receive selegiline due to drug interactions.

For dogs with concurrent behavioral issues such as anxiety or sleep disturbances that are not adequately addressed by selegiline alone, additional interventions may be needed, though many anxiolytic medications are contraindicated with selegiline due to serotonin syndrome risk. Gabapentin may be considered for anxiety and does not carry the same interaction risk as serotonergic medications. Pheromone products, environmental modifications, and behavior management strategies can provide non-pharmacological support for anxiety in dogs with CDS. Melatonin may help regulate disrupted sleep-wake cycles in some dogs, though veterinary guidance should be sought before adding any new treatment.

For dogs with pituitary-dependent hyperadrenocorticism, alternative treatments with generally higher efficacy rates than selegiline include trilostane (Vetoryl), the most commonly used medical treatment for Cushing's disease, and mitotane (Lysodren). These medications have different mechanisms of action and monitoring requirements compared to selegiline. The choice between treatments depends on individual patient factors, owner resources for monitoring, and clinical response. Veterinary endocrinologists may be consulted for complex Cushing's disease cases to help optimize treatment selection and management.